Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Sheng-Li Xue"'
Autor:
Chao-Ling Wan, Yu-Qing Liu, Fang-Tong Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Shuai-Shuai Ge, Miao Wang, Mei-Jing Liu, Zi-Hao Wang, Zheng Li, Sheng-Li Xue, Hai-Ping Dai
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/ba121fd695ca47baa50d149f14d7fca0
Autor:
Jin‐Feng Ma, Jia‐Wei Yan, Mei‐Jing Liu, Chun‐Long Yan, Xiao‐Wen Tang, Hui‐Ying Qiu, Miao Miao, Yue Han, Li‐Min Li, Li‐Qing Kang, Nan Xu, Zhou Yu, Jing‐Wen Tan, Hong‐Jia Zhu, Xu Jia, Zhi‐Zhi Zhang, Miao Wang, Hai‐Ping Dai, Lei Yu, Sheng‐Li Xue, De‐Pei Wu, Wen‐Jie Gong
Publikováno v:
HemaSphere, Vol 8, Iss 10, Pp n/a-n/a (2024)
Abstract Severe cytokine release syndrome (sCRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) have limited the widespread use of chimeric antigen receptor T (CAR T)‐cell therapy. We designed a novel anti‐CD19 CAR (ssCART
Externí odkaz:
https://doaj.org/article/e8bd78da2b4d4b95bc0187ea88dc722c
Autor:
Mei-Jing Liu, Lan Dai, Li Yao, Kai-Wen Tan, Han-Yu Cao, Si-Man Huang, Chao-Ling Wan, Yuan-Hong Huang, Yang Zhang, Wen-Jie Gong, Sheng-Li Xue
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/9b491984e01c422fa237047dcd6ff9de
Autor:
Yan-Yan Li, Shuai-Shuai Ge, Yuan-Hong Huang, Ming-Zhu Xu, Chao-Ling Wan, Kai-Wen Tan, Tao Tao, Hai-Xia Zhou, Sheng-Li Xue, Hai-Ping Dai
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/28a5249897d5441e98a9d67e6f83e339
Autor:
Miao Wang, Han-Yu Cao, Kai-Wen Tan, Qiao-Cheng Qiu, Yuan-Hong Huang, Shuai-shuai Ge, Zi-Hao Wang, Jia Chen, Xiao-Wen Tang, De-Pei Wu, Sheng-Li Xue, Zheng Li, Hai-Ping Dai
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/638f511fdb7145c0811514bbb3eea81b
Autor:
Mei‐Jing Liu, Kai‐Wen Tan, Han‐Yu Cao, Si‐Man Huang, Chong‐Sheng Qian, Sheng‐Li Xue, Hai‐Ping Dai, Wen‐Jie Gong
Publikováno v:
HemaSphere, Vol 8, Iss 2, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/e67c1d859b3b44b58dbb7e4039eecb71
Autor:
Si‐Man Huang, Chao‐Ling Wan, Han‐Yu Cao, Yan‐Yan Li, Chong‐Sheng Qian, Hai‐Xia Zhou, Ming‐Zhu Xu, Xiao‐Hui Hu, Lan Dai, Hai‐Ping Dai, Sheng‐Li Xue
Publikováno v:
Clinical Case Reports, Vol 11, Iss 12, Pp n/a-n/a (2023)
Key Clinical Message There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B‐ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse af
Externí odkaz:
https://doaj.org/article/e00f4ab4696542c7889d7aed2a24ad24
Autor:
Jing-Ying Zou, Si-Man Huang, Hai-Xia Zhoub, Ming-Zhu Xu, Ai-Ning Sun, De-Pei Wu, Sheng-Li Xue, Tong-Tong Zhang
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTObjectives: Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKIs) in preclinical studies for patients with Philadelphia chromosome-positive (Ph+) leukemias. This combination may suggest a novel treatment strategy for
Externí odkaz:
https://doaj.org/article/f1cfee49a2964707ab25a52fd8865ca5
Autor:
Yan Qiu, Chao-Ling Wan, Ming-Zhu Xu, Hai-Xia Zhou, Mei-Jing Liu, Wen-Jie Gong, Li-Qing Kang, Ai-Ning Sun, Lei Yu, De-Pei Wu, Chong-Sheng Qian, Sheng-Li Xue
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/5ac399e240104f459bc6058032c3c523
Autor:
Han-Yu Cao, Hui Chen, Song-Bai Liu, Wen-Jie Gong, Chong-Sheng Qian, Tong-Tong Zhang, Chao-Ling Wan, Si-Man Huang, Nan Xu, Hai-Ping Dai, Sheng-Li Xue
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The treatment of B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system (CNS) involvement poses a significant clinical challenge because most chemotherapeutic agents exhibit weak permeability to the blood-brain barrier (BBB). In addi
Externí odkaz:
https://doaj.org/article/26ca1df7ac334b7e82a4367e4326102c